Company intelligence / Profile preview

Dawon Medax

Seoul, Seoul Teugbyeolsi, South Koreadawonmedax.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Dawon Medax has developed Korea’s first hospital-installable, accelerator-based boron neutron capture therapy system and is developing a proprietary boron drug and treatment planning software. The company has completed animal testing and is proceeding toward regulatory approval, with plans to begin or expand clinical trials of its A-BNCT cancer therapy platform.

Therapeutic areas: Oncology
Modalities: DeviceSmall molecule
Industry: Biotech

Partnerships

Gil Hospital (BNCT development MOU)BPA (drug development & supply MOU)KMEDI hub and KHNP for joint R&D on BNCT systems

Beyond the preview

Go deeper on Dawon Medax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dawon Medax.

Explore the full profile